NK cell therapy for stomach cancer spread to abdomen
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new kind of immune cell therapy (NK cells) designed to target and attack stomach cancer that has spread to the lining of the abdomen. It combines this with standard surgery and chemotherapy to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stomach or gastroesophageal junction cancer that has spread to the lining of your abdomen (peritoneum).
- You must be in fairly good health (able to do daily activities with little or no help).
- You must be willing to have a small surgery to place a port in your abdomen and to give samples.
- You must not be pregnant or breastfeeding, and if you could become pregnant, you must use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial tests a new therapy using your own immune cells (NK cells) that are specially trained to find and attack cancer cells. It is for people with pancreatic cancer that has not responded to previous treatment.
This trial tests a new type of immune cell therapy called CBG131 CAR-T cells for people with advanced stomach or pancreatic cancer that has stopped responding to standard treatments. The therapy targets a protein called CLDN18.2 on cancer cells, and the study aims to see if it can shrink tumors.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
Hear when a new Gastric Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.